Production Platform
Through our core technical capabilities in modern traditional Chinese medicine (TCM) and advanced controlled-release formulations, Baheal Medical has established a sophisticated R&D and production system for both TCM and chemical medicines. We have successfully launched a variety of innovative products with proprietary intellectual property rights, and consistently drive forward technological development and production for upstream medical innovations.
Shanghai - Natural Medicine R&D and Transformation PlatformQingdao - Chemical Drug R&D and Transformation PlatformLangfang - High-end Radiotherapy Industrialization Base
As a natural medicine R&D and transformation platform, it aims to inherit and promote traditional Chinese medicine. With modernization, standardization, and globalization of TCM as its mission, it adheres to the concept of diagnosable diseases, controllable quality, and demonstrable efficacy, building a full industrial chain of modern TCM.
24600㎡
Land Area
2.59Billion tablets
Annual production capacity
As a chemical drug R&D and transformation platform, it focuses on the R&D and commercial production of advanced formulation technologies such as osmotic pumps and pellet coating matrix tablets. The base covers an area of 85,600 m² with a production capacity of 6.5 billion tablets per year.
· Co-production and sales in China and the USA, with multiple products simultaneously registered and sold in both markets.
cGMP Certification by FDA
"Zero Defect", Co-production and sales in China and the USA
85600㎡
Land Area
6.5Billion tablets
Annual production capacity
As a high-end radiotherapy device manufacturing platform that integrates R&D, production, testing, maintenance and training, to achieve “Made in China, Delivered Globally.”
9739㎡
Land Area
100units
Annual production capacity
